Ryan M Phillips
Overview
Explore the profile of Ryan M Phillips including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
86
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dosimetric Features of Ultra-Hypofractionated Intensity Modulated Proton Therapy for Prostate Cancer
Gao R, Ma J, Pisansky T, Kruse J, Stish B, Kowalchuk R, et al.
Int J Part Ther
. 2024 Jun;
12:100015.
PMID: 38827121
Purpose: To report clinical and dosimetric characteristics of 5-fraction stereotactic ablative radiotherapy (SABR) using intensity modulated proton therapy (IMPT) for localized prostate cancer. Materials And Methods: All patients receiving IMPT...
2.
Sutera P, Deek M, Deek R, Guler O, Hurmuz P, Reyhan M, et al.
Adv Radiat Oncol
. 2024 May;
9(7):101507.
PMID: 38799104
Purpose: Emerging data suggest that metastasis-directed therapy (MDT) improves outcomes in patients with oligometastatic castration-sensitive prostate cancer (omCSPC). Prostate-specific membrane antigen positron emission tomography (PSMA-PET) can detect occult metastatic disease,...
3.
McKone E, Sutton E, Johnson G, Phillips R
J Clin Med
. 2024 Jan;
13(2).
PMID: 38256579
Major advances in prostate cancer diagnosis, staging, and management have occurred over the past decade, largely due to our improved understanding of the technical aspects and clinical applications of advanced...
4.
Mahmoud A, Childs D, Ahmed M, Kendi A, Johnson G, Orme J, et al.
Prostate
. 2023 Oct;
84(3):237-244.
PMID: 37899635
Background: Prostate cancer (PCa) parenchymal brain metastases are uncommon and troubling observations in the course of the disease. Our study aims to evaluate the prevalence of brain metastases among PCa...
5.
Tran P, Sutera P, Phillips R, Deek M, Chmura S
Int J Radiat Oncol Biol Phys
. 2022 Oct;
114(4):576-580.
PMID: 36244393
No abstract available.
6.
Kowalchuk R, Kim H, Harmsen W, Jeans E, Morris L, Mullikin T, et al.
Cancer
. 2022 Sep;
128(21):3815-3823.
PMID: 36070558
Background: Patients with high-risk prostate cancer (HRPC) have multiple accepted treatment options. Because there is no overall survival benefit of one option over another, appropriate treatment must consider patient life...
7.
Sutera P, Phillips R, Deek M, Ozyigit G, Onal C, Tran P
J Nucl Med
. 2022 Jan;
63(3):339-341.
PMID: 35058322
No abstract available.
8.
Deek M, Phillips R, Tran P
Semin Radiat Oncol
. 2021 Jun;
31(3):242-249.
PMID: 34090651
Oligometastatic disease was originally defined by Hellman and Weichselbaum as an intermediate-state existing between locally confined and widely disseminated malignancy, whose natural history could be positively impacted with systemic and...
9.
Ahmed M, Phillips R, Sharma V, Davis B, Karnes R
Curr Opin Urol
. 2021 Mar;
31(3):199-205.
PMID: 33742974
Purpose Of Review: Metastases directed therapy (MDT) is an increasingly utilized modality in patients with oligometastatic prostate cancer (OMPC) recurrence. The purpose of our review is to discuss the recent...
10.